Results 111 to 120 of about 259,058 (180)

Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.
Xin Qi   +13 more
wiley   +1 more source

A Rare Case of Appendiceal Metastasis From Prostate Adenocarcinoma in an Asymptomatic Patient With Biochemical Recurrence

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT We report a rare case of appendiceal metastasis from prostate adenocarcinoma in a 73‐year‐old male with a prior Gleason score 7 prostate cancer, initially treated with radical prostatectomy and adjuvant radiation in 2014. The patient presented in 2025 with a rising prostate‐specific antigen (PSA) and modest prostate‐specific membrane antigen ...
Antonio Muina   +3 more
wiley   +1 more source

Prostatic Adenosquamous Carcinoma With a Minute Squamous Component in the Initial Biopsy and Early Liver Metastasis: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction We report a case of de novo prostatic adenosquamous carcinoma with a minute squamous component in the initial biopsy and early liver metastasis despite a marked prostate‐specific antigen response. Case Presentation A 72‐year‐old man was diagnosed with locally advanced prostate cancer with nodal and multiple bone metastases ...
Yohei Tsubouchi   +9 more
wiley   +1 more source

UPDATE ON ANDROGEN DEPRIVATION THERAPY AND ADJUVANT METFORMIN (ADMET) TRIAL FOR MEN WITH TREATMENT NAIVE METASTATIC PROSTATE CANCER

open access: yes, 2016
UPDATE ON ANDROGEN DEPRIVATION THERAPY AND ADJUVANT METFORMIN (ADMET) TRIAL FOR MEN WITH TREATMENT NAIVE METASTATIC PROSTATE ...
J Gunter (13754467)   +8 more
core  

Near‐Obliterative Bulbar Urethral Stricture 12 Years After Artificial Urinary Sphincter Implantation: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Artificial urinary sphincter implantation is guideline‐supported for post‐prostatectomy stress urinary incontinence; however, ultra‐late urethral deterioration remains poorly characterized. Case Presentation A 66‐year‐old man underwent radical retropubic prostatectomy in December 2006, followed by salvage radiotherapy in April ...
Tokiko Niimura   +2 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Off‐midline versus supraumbilical specimen extraction sites in robot‐assisted radical prostatectomy

open access: yesBJU International, Volume 138, Issue 5, Page 886-893, November 2026.
Objectives To compare two different specimen extraction sites (SES) (off‐midline [OM] vs. supraumbilical) for the incidence of incisional hernias (IHs) and to evaluate different risk factors for their occurrence after robot‐assisted radical prostatectomy.
Jonathan Vollemaere   +9 more
wiley   +1 more source

Evaluation of triplet therapy combined with robot‐assisted cytoreductive prostatectomy for high‐volume metastatic prostate cancer: a multicentre randomised controlled trial protocol

open access: yesBJU International, Volume 138, Issue 5, Page 807-814, November 2026.
Background Prostate cancer (PCa) is the second most common cancer in men. For patients with high‐volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended.
Xiangwei Yang   +7 more
wiley   +1 more source

Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer. [PDF]

open access: yesJ Immunother Cancer
Jamroze A   +17 more
europepmc   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

open access: yesCancer Science, Volume 117, Issue 11, Page 3086-3097, November 2026.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy